Search the Site

Twitter

test tubes

$AMRN Amarin Moves Up Clinical Timelines, Again

publication date: Nov 10, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Amarin (NASDAQ:AMRN) reported its quarterly financial results for 3Q10 this morning along with positive updates for its clinical development timeline for AMR101 and corporate developments.



Sorry this page is available to subscribers only. If you're not a subscriber why not join today?

You can also sign up for our 100% FREE Newsletter  to stay current on public webinars, special offers, and news alerts:

FREE NEWSLETTER

If you are already a subscriber, please login.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site including:

- Detailed Reports on Upcoming FDA and Clinical Trial Trades
- REAL TIME Posting of Trades (Entries and Exits)
- Clinical and Regualtory Catalyst Database with over 300 events and updated daily 
- Members Only Live Interactive Webinars 
- Weekly Watchlist
- Email / SMS (Text Message) Alerts of critical news
- Access to view Mark Messier and Mike Havrilla's Trading Accounts
- A More Detailed FDA Calendar
- Direct Email Communication
- Affiliate Program

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.